

IN VIVO

THE BUSINESS & MEDICINE REPORT

WINDHOVER INFORMATION INC. • windhover.com • Vol. 20, No. 2

FEBRUARY 2002



Earthquake scene from Sebastian Munster's Cosmographia © Christell Gerstenberg/CORBIS

Dealmaking Round-Up 2001

For pharma, it's terra infirma: last year's transactions revealed a dramatic power shift from larger to smaller companies, who now see dealmaking as the primary tool for remodeling themselves. On the other hand, consolidation has landlocked the device industry.

Altana Calls Trumps

Fueled by the success of its first blockbuster, pantoprazole, Germany's Altana aims to use two potentially bigger follow-ons to hoist itself into the global league.

ANS Goes Along for the Ride

With much-larger Medtronic leading the way, ANS hopes not to unseat its main rival in neurostimulation, but simply to tag along for the ride.

Starting in the Marketplace

InterMune was formed around gamma interferon, a marketed drug licensed from Genentech. Now, it is expanding the cytokine's clinical profile, giving it momentum, visibility, and the bona fides to attract additional late-stage products.

Invatec: Italy's Home-Grown Device Model

Can this family-run company continue providing superior technology and responsiveness during the transition from OEM supplier to an interventional vascular products company?

The Best of Three Worlds

Applera has installed an experienced management team to guide it into a new era of high-margin molecular diagnostics and to leverage existing resources in discovery, assay development, and systems.

NEW COLUMN: Sales Force Impact • Tyco Healthcare loses its umbrella

